307 related articles for article (PubMed ID: 17848841)
1. Efficacy and safety of a new ready-to-use recombinant human growth hormone solution.
Romer T; Peter F; Saenger P; Starzyk J; Koehler B; Korman E; Walczak M; Wasik R; Ginalska-Malinowska M; Solyom E; Berghout A
J Endocrinol Invest; 2007; 30(7):578-89. PubMed ID: 17848841
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial].
Hou L; Luo XP; Du ML; Ma HM; Gong CX; Li YC; Shen SX; Zhao ZH; Liang L; Dong GP; Yan CY; Du HW
Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):48-52. PubMed ID: 19573383
[TBL] [Abstract][Full Text] [Related]
3. The -202 A allele of insulin-like growth factor binding protein-3 (IGFBP3) promoter polymorphism is associated with higher IGFBP-3 serum levels and better growth response to growth hormone treatment in patients with severe growth hormone deficiency.
Costalonga EF; Antonini SR; Guerra-Junior G; Mendonca BB; Arnhold IJ; Jorge AA
J Clin Endocrinol Metab; 2009 Feb; 94(2):588-95. PubMed ID: 18984657
[TBL] [Abstract][Full Text] [Related]
4.
Gomez R; Khadilkar V; Shembalkar J; Chu DM; Ko CW; Wajnrajch MP; Wang R
J Pediatr Endocrinol Metab; 2024 Jun; 37(6):525-531. PubMed ID: 38717038
[TBL] [Abstract][Full Text] [Related]
5. Seven years of safety and efficacy of the recombinant human growth hormone Omnitrope in the treatment of growth hormone deficient children: results of a phase III study.
Romer T; Saenger P; Peter F; Walczak M; Le Bouc Y; Khan-Boluki J; Berghout A
Horm Res; 2009; 72(6):359-69. PubMed ID: 19844125
[TBL] [Abstract][Full Text] [Related]
6. Two-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age.
Schwarz HP; Walczak M; Birkholz-Walerzak D; Szalecki M; Nanu M; Woehling H; Schuck E
Adv Ther; 2016 Mar; 33(3):423-34. PubMed ID: 26886776
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and efficacy of the recombinant human growth hormone Omnitrope® in the treatment of Spanish growth hormone deficient children: results of a phase III study.
López-Siguero J; Borrás Pérez MV; Balser S; Khan-Boluki J
Adv Ther; 2011 Oct; 28(10):879-93. PubMed ID: 21948492
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind study to assess the efficacy and safety of valtropin, a biosimilar growth hormone, in children with growth hormone deficiency.
Peterkova V; Arslanoglu I; Bolshova-Zubkovskaya E; Romer T; Zdravkovic D; Kratzsch J; Ji HJ; Savoy C; Saenger P
Horm Res; 2007; 68(6):288-93. PubMed ID: 17627092
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study.
Deal CL; Steelman J; Vlachopapadopoulou E; Stawerska R; Silverman LA; Phillip M; Kim HS; Ko C; Malievskiy O; Cara JF; Roland CL; Taylor CT; Valluri SR; Wajnrajch MP; Pastrak A; Miller BS
J Clin Endocrinol Metab; 2022 Jun; 107(7):e2717-e2728. PubMed ID: 35405011
[TBL] [Abstract][Full Text] [Related]
10. A Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency.
Moore WV; Nguyen HJ; Kletter GB; Miller BS; Rogers D; Ng D; Moore JA; Humphriss E; Cleland JL; Bright GM
J Clin Endocrinol Metab; 2016 Mar; 101(3):1091-7. PubMed ID: 26672637
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of LB03002, a once-weekly sustained-release human GH for 12-month treatment in Korean children with GH deficiency.
Hwang JS; Lee HS; Chung WY; Han HS; Jin DK; Kim HS; Ko CW; Lee BC; Lee DY; Lee KH; Shin JH; Suh BK; Yoo HW; Ji HJ; Lee JH; Bae YJ; Kim DH; Yang SW
Eur J Endocrinol; 2013 Aug; 169(2):179-85. PubMed ID: 23682096
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of Omnitrope®, a somatropin biosimilar, in children requiring growth hormone treatment: Italian interim analysis of the PATRO Children study.
Iughetti L; Tornese G; Street ME; Napoli F; Giavoli C; Antoniazzi F; Stagi S; Luongo C; Azzolini S; Ragusa L; Bona G; Zecchino C; Aversa T; Persani L; Guazzarotti L; Zecchi E; Pietropoli A; Zucchini S
Ital J Pediatr; 2016 Nov; 42(1):93. PubMed ID: 27809913
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human growth hormone plus recombinant human insulin-like growth factor-1 coadministration therapy in short children with low insulin-like growth factor-1 and growth hormone sufficiency: results from a randomized, multicenter, open-label, parallel-group, active treatment-controlled trial.
Backeljauw PF; Miller BS; Dutailly P; Houchard A; Lawson E; Hale DE; Reiner B; Sperling MA;
Horm Res Paediatr; 2015; 83(4):268-79. PubMed ID: 25765099
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of Valtropin in the treatment of short stature in girls with Turner's syndrome.
Peterkova V; Savoy C; Bezlepkina O; Ivanov A; Orlova E; Nagaeva E; Kim J; Lee YP; Saenger PH; Stanhope R
J Pediatr Endocrinol Metab; 2004 Oct; 17(10):1429-34. PubMed ID: 15526722
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of a biosimilar recombinant human growth hormone (r-hGH Cristalia) compared with reference r-hGH in children with growth hormone deficiency (CERES study): A randomized, multicentric, investigator-blind, phase 3 trial.
Czepielewski MA; Garret Q; Vencio SAC; Rassi N; Felicio JS; Faria MS; Senn CCP; Bronstein MD; Cerqueira MJAG; Neves ACL; Sgarbi JA; Spinola-Castro AM; Cunha MPR; Bandeira F; Toffoletto O; Afiune J; Baradelli R; Rodrigues DG; Scharf M
Growth Horm IGF Res; 2019; 48-49():29-35. PubMed ID: 31493626
[TBL] [Abstract][Full Text] [Related]
16. [Effect of recombinant human growth hormone on glucose metabolism in children with growth hormone deficiency].
Liang L; Zou CC; Li Y; Wang CL; Jiang YJ; Dong GP; Fu JF; Wang XM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):657-61. PubMed ID: 17217656
[TBL] [Abstract][Full Text] [Related]
17. Reduced Effectiveness and Comparable Safety in Biweekly
Sun C; Lu B; Liu Y; Zhang Y; Wei H; Hu X; Hu P; Zhao Q; Liu Y; Ye K; Wang K; Gu Z; Liu Z; Ye J; Zhang H; Zhu H; Jiang Z; Liu Y; Wan N; Yan C; Yin J; Ying L; Huang F; Yin Q; Xi L; Luo F; Cheng R
Front Endocrinol (Lausanne); 2021; 12():779365. PubMed ID: 34899612
[TBL] [Abstract][Full Text] [Related]
18. Growth response to an individualized versus fixed dose GH treatment in short children born small for gestational age: the OPTIMA study.
Jung H; Land C; Nicolay C; De Schepper J; Blum WF; Schönau E
Eur J Endocrinol; 2009 Feb; 160(2):149-56. PubMed ID: 19039085
[TBL] [Abstract][Full Text] [Related]
19. Effects of recombinant human growth hormone for 1 year on body composition and muscle strength in children on long-term steroid therapy: randomized controlled, delayed-start study.
Simon D; Alberti C; Alison M; Le Henaff L; Chevenne D; Boizeau P; Canal A; Ollivier G; Decostre V; Jacqz-Aigrain E; Carel JC; Czernichow P; Hogrel JY
J Clin Endocrinol Metab; 2013 Jul; 98(7):2746-54. PubMed ID: 23626006
[TBL] [Abstract][Full Text] [Related]
20. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency.
Guevara-Aguirre J; Rosenbloom AL; Vasconez O; Martinez V; Gargosky SE; Allen L; Rosenfeld RG
J Clin Endocrinol Metab; 1997 Feb; 82(2):629-33. PubMed ID: 9024266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
